ProSense® Cryoablation Technology: A Remarkable Advancement in Tumor Treatment
IceCure Medical Ltd. is drawing significant attention with its ProSense® system, an innovative cryoablation technology that provides a more effective and less invasive option for treating tumors. This technique utilizes liquid nitrogen, which is proven to be both safer and more economical compared to conventional argon-based systems.
Independent Study Confirms ProSense® Safety and Effectiveness
A study conducted by Dr. Franco Orsi, a specialist in interventional radiology, revealed an outstanding technical success rate of 97.7% for the ProSense® system. Focusing on 85 patients, the study assessed their experiences with 96 tumors found in various locations, including the lungs, bones, and soft tissues. The results emphasize that ProSense® efficiently targets tumors while keeping complication rates low during and after the procedure.
Benefits of Liquid Nitrogen in Cryoablation
The study clearly demonstrated that liquid nitrogen-based cryoablation methods, such as ProSense®, offer significant advantages in terms of versatility and user-friendliness. Unlike argon systems that demand general anesthesia and have substantial storage needs, ProSense® can frequently be used in an office setting with local anesthesia. This is critical for enhancing patient satisfaction and improving clinical efficiency.
Minimizing Patient Burden with Less Invasive Procedures
Minimally invasive therapies are becoming the go-to choice for many patients, especially those dealing with various health issues or seeking to avoid traditional surgeries. IceCure's ProSense® system acts as a practical solution, providing convenience while ensuring it remains safe and effective. Any minor complications encountered were manageable and didn't detract from the overall positive feedback regarding the procedure.
ProSense® Utilization in Clinical Settings
The independent study further reinforced the effectiveness of the ProSense® system across a variety of lesion types. With an impressive 97.7% success rate, it showcases its capability to treat both benign and malignant tumors. Additionally, two prior studies indicated high recurrence-free rates for lung cancer treatment, reinforcing ProSense® as a valuable asset in the field of oncology.
The Future of Cryoablation Technology
As more data emerges regarding the safety and efficacy of cryoablation with ProSense®, IceCure Medical is set to expand its applications in oncology. Future focus areas include breast, kidney, and lung cancers, demonstrating a commitment to enhancing treatment options for patients around the globe.
About IceCure Medical
IceCure Medical is publicly traded on NASDAQ under the ticker ICCM. The company is committed to developing advanced cryoablation technologies, aiming to change the way tumors are treated using less invasive techniques. The firm’s global market presence reflects the increasing acceptance of their innovative solutions, particularly in markets like the US, Europe, and China.
Frequently Asked Questions
What is ProSense® by IceCure Medical?
ProSense® is a cryoablation system that employs liquid nitrogen to freeze and destroy tumors, serving as a minimally invasive alternative to surgical removal.
What was the technical success rate of ProSense®?
The independent study reported a technical success rate of 97.7% for ProSense® when treating various types of tumors.
How does ProSense® compare to argon-based systems?
ProSense® presents several advantages, including easier management, cost efficiency, and the capability to perform procedures using local anesthesia, which is not feasible with argon systems.
What types of tumors can ProSense® treat?
ProSense® has proven useful in treating both benign and malignant tumors located in bones, lungs, and soft tissues.
Where can I find more information about IceCure Medical?
For more details, feel free to email investors@icecure-medical.com or get in touch with IR representatives directly.
